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Abstract
Introduction: It is still uncertain whether metastasis is predominantly an early or late event in tumor progression.
The detection of early metastases and cells responsible for the dissemination may therefore have significant clinical
implications.
Methods: Lung dissemination and/or metastasis were investigated in mice carrying the polyomavirus middle-T
oncogene (PyMT) during different stages of mammary tumorigenesis using the colony forming assay.
Immunocytochemical or immunohistochemical staining was used to identify subpopulations of cells responsible for
lung dissemination and metastasis. Histological examination was used to show primary and metastatic tumors. The
tumor-initiating and metastatic capacity of cells expressing stem cell markers was assessed in syngeneic wild-type
(WT) mice whose mammary fat pads were injected with these cells.
Results: Metastatic mammary epithelial cells were detected in the lungs of mice carrying the PyMT oncogene
(MMT mice). These cells were observed early in breast tumorigenesis when the mammary tree appeared by
histological inspection to be normal (or at a premalignant stage), suggesting the possession of disseminating and
metastatic capacity even before full malignant transformation. Some of the disseminated cells and lung metastases
displayed surface stem cell markers. These findings suggest that stem cells from apparently precancerous primary
lesions could be a source of metastasis. Indeed, injection of lung tissue cells from MMT mice into syngeneic WT
mice resulted in the formation of mammary tumors. These tumors resembled their parent mammary tumors in the
MMT donors as well as grafted tumors derived from mammary tumor cells. Furthermore, when we injected lung
tissue cells from GFP MMT mice into the fat pads of recipient WT mice, disseminated or metastatic GFP-expressing
cells were detected in the lungs, lymph nodes and blood of the recipient WT mice. We finally identified a
subpopulation of mammary epithelial/tumor cells expressing CD44 and Sca1 that was largely responsible for
dissemination and metastasis in MMT mice.
Conclusions: The tumorigenic and metastatic potential of a subpopulation of mammary epithelial/tumor cells in
MMT mice is endowed relatively early in mammary neoplasms and suggests a potential role for cancer stem cell
sub-populations in metastasis.
Introduction
Metastasis is a complex, multi-step process in which
cells from primary tumors invade surrounding tissues,
intravasate into the circulation (circulating tumor cells),
arrest in the capillary beds, and extravasate from the cir-
culation into the distant organ. These disseminated
tumor cells may remain in a quiescent state in the new
home but then proliferate and develop into vascularized
metastatic tumors years later in a process stimulated by
unknown factors that may include signals received from
the environmental niche [1,2]. Some prevailing models
of metastasis contend that genetic mutations accumulat-
ing late during multi-stage tumorigenesis provide a
selective advantage that permits tumor cells to metasta-
size [3]. In support of this notion is the clinical observa-
tion that metastasis is often diagnosed in primary
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surgery often cures the disease [4,5]. Thus, metastatic
capacity is considered a relatively late process in tumor
progression [6]. However, contrasting models of metas-
tasis propose that some tumor cells may possess meta-
static properties in the earlier stages of tumorigenesis
[7,8]. Metastasis appears to be an inefficient process. For
example, although 90% of intravenously injected mela-
noma cells could colonize the liver, only about 0.02% of
the cells developed into macrometastases [9]. Thus, the
metastatic potential of tumor cells entering the circula-
tory system is not necessarily uniform and only a few
cells possess the capacity to migrate to the remote
organs, proliferate, and become metastatic tumors.
Although the origin and true identity of the metastatic
cells capable of forming macrometastasis remain elusive,
recent studies indicate that subpopulations of tumor
cells with tumor-initiating ability are candidates because
they can survive in foreign microenvironments and
evolve into heterogeneously metastatic tumor [8]. These
cells are sometimes called cancer stem cells (CSC)
because they also express markers detected on the sur-
faces of normal tissue stem cells. CSC are sub-popula-
tions of tumors found both in hematopoietic
malignancies [10,11] and solid tumors, including breast
cancer [12-15]. CSC possess the properties of self-
renewal and multipotency that may be critical for the
survival of disseminated cells and development of het-
erogeneous macrometastasis. In addition, recent studies
provide evidence that cells from premalignant lesions
and ductal carcinomas in situ (DCIS) can migrate and
develop into fully developed malignant tumors [16,17].
Precancerous stem cells (pCSC) have been identified in
preleukemic clones, mammary intraepithelial neoplasia
outgrowths (premalignant lesions) and precancerous
stem cell lines [18-20]. Injection of pCSC into SCID
mice resulted in the development of benign or malig-
nant tumors [18]. Despite these findings, it remains
uncertain at which stage a developing cancer or precan-
cerous cell becomes endowed with metastatic capacity.
In addition, the cell subpopulations responsible for early
metastasis have not been characterized. It is, however,
evident that the identification of cells responsible for
initiating metastasis has significant clinical implications.
Targeted therapy against these cells would become
feasible.
We previously investigated the role of telomerase and
telomere maintenance in mammary tumorigenesis and
metastasis in mice that carry the polyomavirus middle T
(PyMT) oncogene (MMT mice). Metastasis was found
in lung tissue collected from telomerase-proficient
MMT mice, whereas we failed to detect tumor metasta-
sis in the sections of lungs from telomerase-deficient
MMT mice [21], suggesting that distant metastasis in
MMT mice requires telomerase activity. We found in
these studies that MMT mice are reliable tumor models
with predictable rates of mammary tumor growth and
lung metastasis. In the present study, we have investi-
gated metastasis triggering events that may occur early
in tumorigenesis and attempted to identify cell sub-
populations potentially responsible for metastasis. Our
experiments show that subpopulations of premalignant
mammary epithelial cells (MECs) developing in these
mice are endowed with the capacity of dissemination. In
addition, their ability to disseminate and form tumors
could be maintained after transfer of the primary malig-
nant cells to a new host devoid of overt oncogene
expression. Furthermore, a subset of cells bearing CSC
markers in the primary and metastatic lesions could be
detected during the various stages of mammary tumori-
genesis and they appeared to play an important role in
tumor dissemination and metastasis. The present studies
therefore support a model of parallel development of
primary and secondary tumors.
Materials and methods
Mice
The mice (C57BL/6 background) used in our experi-
ments include female mice transgenic for the PyMT
(MT mice) oncogene driven by the mouse mammary
tumor virus long terminal repeat (MMTV-LTR) and
MMT mice double transgenic for PyMT and the human
MUC1 antigen (mucin 1) [22,23] (a kind gift from San-
dra J. Gendler, Mayo Clinic, Scottsdale, AZ, USA). Mice
expressing PyMT develop mammary carcinomas [24],
and the MUC1 antigen is expressed in a tissue-specific
fashion similar to that in humans [22]. GFP mice
(C57BL/6-Tg, CAG-EGFP) were purchased from the
Jackson Laboratory (Bar Harbor, MN, USA) and crossed
over MMT mice to generate GFP MMT mice. Wild-
type (WT) female C57BL/6 mice (C57BL/6NTac) were
purchased from Taconic Farms (Germantown, NY,
USA) and used as recipient mice to determine the
tumorigenic and metastatic potential of cells isolated
from lungs or mammary glands of MMT mice. Animals
were maintained in microisolator cages under specific
pathogen-free conditions. The use of mice was approved
by the Institutional Animal Care and Use Committee of
Boston University Medical Center.
PCR
PCR analysis was used to confirm the presence of the
MUC1, PyMT and GFP genes in transgenic mice. Tail
tissue DNA was extracted using the REDExtrac-N-Amp
Tissue PCR Kit (Sigma, Steinheim, Germany). A 100
nM sample of 5’-AGTCACTGCTACTGCACCCAG-3’
forward primer and 5’-CTCTCCTCAGTTCCTCGCT
CC-3’ reverse primers were used for the MT gene and
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ACGTCGTGGACATTGATG-3’ for the MUC1 gene.
Primers for the detection of GFP gene include 5’-
AAGTTCATCTGCACCACCG-3’ (forward), 5’-TCCTT
GAAGAAGATGGTGCG-3’ (reverse), and internal
positive control 5’-CTAGGCCACAGAATTGAAA-
GATCT-3’ (forward), 5’-GTAGGTGGAAATTCTAG-
CATC AT CC-3’ (reverse). PCR was carried out using
these primers as well as the additional reagents: 10 μl
2 × PCR mix, 4 μl tail DNA, and reagent quality water.
Size fractionation in a 1.5% agarose gel was used to ana-
lyze the PCR products [23].
Whole mount and H&E staining
Mice were sacrificed at the indicated ages. For whole-
mount preparations, thoracic mammary glands (three
pairs) were harvested and the resected tissue was spread
onto a slide and fixed in Carnoy’s fixative (60% ethanol,
30% chloroform, 10% glacial acetic acid) for two to four
hours at 4°C. The tissue mount was then washed in 70%
ethanol for 15 minutes, 50% ethanol for 15 minutes,
rinsed with distilled water for five minutes and placed in
a Carmine Alum staining solution over night. Stained
whole mammary glands were kept in 70% ethanol at 4°C
for photograph. The solid masses as indicated by the
deep red-staining with Carmine Alum and greater than
1m m
2 areas were measured using Spot Advanced™
digital imaging software (Diagnostic Instruments, Inc.,
Sterling Heights, MI, USA). For H&E staining, mam-
mary glands were paraffin-embedded, sectioned (5 μm),
stained with H&E, and examined under light
microscope.
Colony-forming assay for proliferating cells in lung tissue
To identify the presence of disseminated cells in the
lungs, a 24 G needle was used to perfuse the lungs of
blood with sterile PBS via the right ventricle of the
heart before harvesting the lung tissue. The lungs were
collected, minced and digested in a collagenase enzyme
cocktail solution as previously described [21,25]. Single
cells were cultured in 10% FCS Dulbecco’s modification
of Eagle’sm e d i u m ™ (DMEM) for two weeks and
stained with anti-CD44 (clone IM7), anti-Sca1 (clone
D7) (e-Bioscience, Inc., San Diego, CA, USA), anti-ER
(clone MC-20), (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) or anti-MUC1 (clone HMPV) (BD
Pharmagen, San Diego, CA, USA) antibodies using stan-
dard immunocytochemical (ICC) staining. Presence of
disseminated or metastatic tumor cells was determined
by growth of tumor colonies on tissue culture plates
and colonies were detected with 0.5% crystal violet
staining. Each colony (> 50 cells) showing either MUC1
or GFP positivity was counted to quantify the number
of disseminated cells for each individual mouse.
Immunocytochemical staining
The mammary tumors and perfused lungs were minced
and incubated overnight in DMEM with 10% FCS, 2
mM L-glutamine, and 100 μg/ml of both penicillin and
streptomycin (Cellgro, Mediatech, Inc., Manassas, VA,
USA) in a Heracell CO2 incubator at 37°C and 5% CO2.
Lung tissue cells were purified using 5 ml Ficoll-Paque
PLUS™ solution (GE Healthcare, Piscataway, NJ, USA)
to remove dead cells and then stained with antibodies
against CD44, Sca1, MUC1 and/or epithelial specific
antigen (ESA, clone G8.8) (e-Bioscience, San Diego, CA,
USA) using standard ICC staining method. A similar
method was used to analyze the GFP-positive metastatic
cells that co-expressed ESA in the blood, lymph nodes
(LNs), and lungs of WT-recipient mice.
Injection of lung tissue cells or mammary tumor cells into
wild-type recipients
WT mice were anesthetized via intraperitoneal injection
of ketamine (100 mg/kg) plus xylazine (10 mg/kg).
Matrigel suspensions 1:1 of lung cells ranging in number
from 1 × 10
3 to 1 × 10
6, from MMT or GFP MMT
mice at different stages of tumorigenesis were injected
into mammary fat pads [26,27]. In some experiments,
the CD44 and Sca1 double-positive (CD44/Sca1
+)a n d
double-negative (CD44/Sca1
-) cells obtained by cell sort-
ing from MECs, mammary tumors, or lungs of GFP
MMT mice were transplanted to WT mice using the
same method. The MECs were isolated according to the
method previously described [28] with modifications.
T h em i c ew e r ef o l l o w e df o ru pt ot w om o n t h s ,a t
biweekly intervals for the growth of tumors. At the end
of experiment the mice were sacrificed and the lungs,
draining LNs and mammary tumors, if any, were har-
vested and examined.
Statistical analysis
For samples in which actual mean values could be
attained, including mammary masses (mm
2)a n dt h e
number of lung cell colonies formed, one-way analysis
of variance (ANOVA) was used to determine P values. P
values of less than 0.05 were considered statistically sig-
nificant. To compare percentages of positive-staining
tumor cells between age groups of mice, the Chi-Square
test was used to determine the P values. The statistical
analysis software, SPSS Statistics™ v17.0 (IBM Corpora-
tion, Somer, NY, USA), was used to attain these values.
Results
Detection of disseminated cells or metastasis in the lungs
of young MMT mice
MMT mice transgenic for PyMT and MUC1 develop
mammary tumors in multiple stages (Figures 1a and
1b). The mammary trees in such mice appeared normal
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lesions then evolved into defined solid masses at around
an age of 60 days and finally became diffuse invasive
tumors by 116 days (Figure 1a). H&E-stained sections
from breast tissue at each of these ages are shown
below and support these conclusions (Figure 1a, lower
panels). By contrast, mammary trees in PyMT-negative
MUC1 transgenic (MUC1.Tg) mice remain unchanged
with few side branches and we did not observe overt
tumorigenesis (Figure 1a; right panel). Based on our
observations of mammary tumor development [21],
MMT mice were arbitrarily stratified into three age
groups for purpose of experiment, including: 20 to 35
days (hyperplastic lesion), 53 to 87 days (mammary
intraepithelial neoplasms (MIN), a premalignant stage),
and 98 to 170 days (malignant stage) and compared
with control MT and MUC1.Tg mice. Significant
increases in total solid tumor mass were observed in the
breast tissues of the 53 to 87 days and 98 to 170 days
groups (Figure 1b).
We next investigated the relative levels of viable disse-
minated cells using an in vitro colony-forming assay to
detect cells with proliferative potential within the lung
tissues. In general, the proportion of colony-forming
cells in the lungs increased with the average age of these
MMT mice (Figures 1c and 1d). Surprisingly, culture of
lung tissue cells from mice as young as 26 days postna-
tal resulted in tumor colony formation (Figures 1c and
1d). Furthermore, metastatic tumors were found in mice
at an age of 60 days (Figure 1c, lower panels). Before
processing for colony-forming assay, lungs were care-
fully perfused to remove circulating cells [see Additional
data file 1]. Thus, the colony-forming cells in the culture
of lungs likely represent the disseminated and/or
Figure 1 Development of mammary tumors and detection of disseminated and/or metastatic cells in MMT mice.( a) Mammary glands
were harvested from mice double transgenic for PyMT and MUC1 antigen (MMT) or MUC1 transgenic (MUC1.Tg) mice at indicated ages,
processed for whole mount or sections and stained with H&E. The solid masses are indicated by circles. (b) Comparison of mammary masses in
different age groups (n = three to seven per group) of MMT, MUC1.Tg and MT (mice transgenic for PyMT oncogene) mice. The whole mount
was digitized and the solid masses were traced and measured using SPOT advanced software. (c) Detection of disseminated cells or metastasis
in lungs. Lungs were harvested from MMT mice at the indicated ages and perfused to remove circulating cells. The lung tissue was minced and
digested in a collagenase enzyme cocktail solution. The cells were then cultured on tissue culture plates for two weeks and stained with 0.5%
crystal violet (upper panels). Lungs from mice at the indicated ages were processed for histological examination with H&E staining. The green
square indicates the enlarged area. (d) Colonies of more than 50 cells from lung cell cultures of each mouse (n = three to seven per group)
were counted. Statistical analysis was performed using one-way analysis of variance.
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carcinomas as MMTV-PyMT expression has not been
shown to lead to direct transformation of lung cells
[24]. In repeated experiments, we failed to observe col-
ony formation in lung tissue from the control MUC1.Tg
mice, which do not develop breast carcinoma (Figures
1c and 1d). Consistent with previous findings [23],
expression of MUC1 in MMT mice did not alter mam-
mary tumorigenesis or metastasis since comparable
tumor sizes and numbers of lung colonies were
observed between MT and MMT mice (Figures 1b and
1d). These experiments suggest that lung dissemination
or metastasis may be an early event in mammary tumor-
igenesis of MMT mice.
Lung-derived cells from MMT mice contain a sub-
population expressing CD44 and Sca1 with mammary
tumor cell morphology
We next further characterized the colony-forming cells
in the lungs of MMT mice. Lung-derived colonies were
stained with a panel of antibodies against cancer stem
cell and mammary carcinoma markers. Surprisingly,
most of the colony-forming cells were positive for the
cancer stem cell markers CD44 and Sca1 (Figure 2a). In
addition, the morphology of these colony-forming lung
cells resembled that of primary mammary cancer cells
in Figure 2b.
We next examined single cell suspensions prepared
from the lungs of MMT mice at different stages of
mammary cancer progression. Our hypothesis was, if
CD44
+ and Sca1
+ cells are involved in metastasis to the
lung from primary mammary carcinomas, we should be
able to find such cells in the lungs. Single cell suspen-
sions obtained from the lungs of MMT mice at increas-
ing ages were therefore stained with monclonal
antibodies against CD44, Sca1 or MUC1 and examined
under microscopy. Primary mammary tumor cells from
MMT mice were used as positive control in the left
panels of Figure 2b. Red-stained CD44, Sca1, or MUC1-
positive cells were identified among the lung tissue cells
prepared from MMT mice at each age group, although
an age-dependent increase in cells expressing each of
these markers was observed (Figure 2c). Comparable
numbers of CD44
+ or Sca1
+ cells were observed in each
age group between MT and MMT mice, suggesting that
the expression of MUC1 does not affect the pool of
CD44
+ or Sca1
+ cells (Figure 2c). In addition, the major-
ity of the CD44/Sca1
+ lung cells also expressed the sur-
face markers CD24, ESA, or estrogen receptor (ER) at
levels comparable with those expressed by primary
tumor cells (Figures 2d and 2e). These experiments indi-
cate that cells bearing stem cell, tumor or mammary
epithelial markers can be identified in the lungs of
MMT mice, suggesting that they originate from
mammary epithelial/tumor cells and may be important
seeding cells of lung metastasis.
The tumorigenic potential of lung tissue cells from MMT
mice
We next assessed the tumorigenic potential of these
lung tissue cells that possess the properties of colony
formation and expression of CSC markers. Single cell
suspensions obtained from the lungs of MMT mice at
the various stages of mammary tumor progression were
injected into the mammary fat pads of WT mice. A
t o t a lo f2 2W Tm i c ew e r eu s e d ,o fw h i c h1 6r e c e i v e d
lung tissue cells from MMT mice, three WT mice
received lung tissue cells collected from MUC1.Tg mice
as negative controls, and three WT mice were injected
with CD44
+ tumor cells sorted from primary MMT
mammary tumors, as positive controls. As shown in Fig-
ures 3a and 3b, injection of lung tissue cells from MMT
mice into the fat pads of WT mice resulted in tumor
growth in 75% (12 out of 16) of the mice. By contrast,
there was no evidence for mammary tumor formation in
mice injected with lung cells from control MUC1.Tg
mice. By stratifying MMT donor mice according to age,
we were able to detect an age-dependent trend in tumor
initiation potential in lung metastatic cells (Figure 3b).
Of recipient mice, 33.3% developed mammary tumors
when they were injected with lung tissue cells from
MMT mice at ages between 20 and 35 days. In the
other groups of WT mice, it was found that four out
of six and all seven mice that received lung tissue cells
from MMT mice at 53 to 70 days and 94 to 170 days
old, respectively, developed mammary tumors (Figure
3b). Tumor formation in each group was further con-
firmed by histological examination (Figure 3c). By con-
trast, we detected no mammary tumor formation in
WT mice injected with lung cells from MUC1.Tg con-
trol mice (Figure 3a). The morphology of tumors in
WT mice derived from MMT mouse lung tissue cells
resembled the primary mammary tumors in MMT
mice (data not shown) as well as grafts of CD44
+
tumor cells into WT mice (Figure 3c). In addition, the
level of CD44 and Sca1 expression in the grafted
tumors was comparable with that in the grafts of
CD44
+ tumor cells (Figure 3d). Interestingly, Sca1-
positive cells could be identified inside blood vessels in
tissue sections of the grafted tumor in WT mice
injected with lung tissue cells from a 70-day-old MMT
donor mouse (Figure 3d). Taken together, these results
suggest that breast migrants and metastases in lung
tissue contain a subpopulation of cells expressing stem
cell markers with tumorigenic potential, that these
cells migrate to lungs early in mammary tumorigenesis,
and that lung metastasis increases with progression of
the primary tumor.
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transplanted lung tissue cells from MMT mice
We next determined whether disseminating and meta-
static potential could be transferred from cells growing
in the lungs of MMT mice to the mammary fat pads of
WT mice. We then used the colony-forming assay to
examine the levels of viable, proliferating cells in the
lungs of these mice. Indeed lung colonies were observed
after this procedure (Figure 4). Tumor colony frequency
increased in the age of 53 to 70 day donor mice
although a significant number of colonies were still
observed in the lungs of WT mice receiving lung tissue
cells from young MMT mice (Figure 4a). By contrast,
we have observed minimal colony formation in the lung
tissue cells of control WT mice injected with lung tissue
cells from MUC1.Tg mice (Figure 4a). Some cells in the
colonies were positive for ER expression (Figure 4b),
suggesting a mammary epithelial origin. In addition,
MUC1/Sca1 double-positive (red/blue) cells were also
observed in the lung tissue cells of WT mice that were
injected with mammary tumor cells or lung tissue cells
from MMT donor mice at different age groups (Figure
4c). It should be noted that the MUC1 expression in
these cells was diffuse and spread over the entire cell,
one of the characteristics of mammary carcinoma cells
in MMT mice (Figure 4c). To confirm whether CD44/
Figure 2 Detection of cells expressing stem cell markers or MUC1 in the lungs of MMT mice.( a) Immunocytochemical (ICC) staining. The
colonies growing from lung tissue cells (as in Figure 1) were stained with anti-CD44 or Sca1 antibodies. The cells staining red were positive cells
and those stained purple were considered double-positive cells (10x). The red square indicates the enlarged area. (b) Single-cell suspensions
were made from the lungs of mice double transgenic for PyMT and MUC1 antigen (MMT) at the indicated ages and stained with monoclonal
antibodies against CD44, Sca1 or MUC1 using ICC staining. Cells isolated from mammary tumors of MMT mice were used as positive control.
Cells staining red were considered positive (60x). (c) Comparison of positive cells among different age groups (n = three to eight per group) of
MMT and MT mice. The cells positive for the indicated antibody from each mouse were counted and are presented in the bar graph. Statistical
significance between groups was determined using Chi-square test and the symbol “*” indicates P < 0.05 when 20 to 35 day group was
compared with 53 to 87 day or 98 to 170 day groups. (d and e) Expression of CD24, ESA (epithelial specific antigen) or estrogen receptor (ER)
on CD44/Sca1
+ cells. The lung cells isolated from MMT mice at the indicated ages were processed for staining with anti-CD44-Cy, Sca1-FITC and
CD24-PE, ESA-PE or ER-PE antibodies. The percentage of cells double positive for CD44 and Sca1 were gated and then further analyzed by FACS
for expression of CD24, ESA or ER. The percentage of gated CD44/Scal
+ cells in total lung or tumor cells and percentage of triple-positive cells
are presented. (e) Mammary tumor cells isolated from 162-day-old MMT mice were used as controls.
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+ lung cells could seed metastasis, CD44/Scal
+ cells
obtained by cell sorting from mammary tumors or lungs
of MMT mice at ages of more than 120 days were
injected into the WT mice. Lung metastasis was
observed in mice injected with CD44/Scal
+ tumor cells
(Figure 4d). In addition, the metastatic tumor expressed
ER, confirming its mammary epithelial origin (Figure 4d,
right panel). Together, these results indicate that lung
tissue cells from MMT mice at various stages of tumor
progression could result both in forming primary
tumors in recipient fat pad and in seeding tumor disse-
mination and metastasis in recipient syngeneic WT
mice. Our studies appear to suggest an inherent tumori-
genic and metastatic capability within MMT cells bear-
ing stem cell markers.
Disseminating and metastatic potential of lung and
mammary tumor cells from GFP MMT mice
Our findings of lung metastatic cells in recipient WT
mice suggest that disseminated tumor cells should be
detectable in various tissues outside the primary tumor,
including blood and LNs. To facilitate the identification
of the disseminated tumor cells, we next generated
green fluorescent protein (GFP) MMT mice. Firstly, in
Figure 5a, we showed that the intracellular expression of
GFP did not alter mammary tumorigenesis, making this
a viable tumor model. However, mammary epithelial/
tumor cells expressing GFP were easily identified by
fluorescence microscopy in WT mice transplanted with
tumor cells from GFP MMT mice. Single cell suspen-
sions of lungs were obtained from GFP MMT mice at
various stages of tumorigenesis (after the lungs were
perfused to remove the circulating tumor cells), and
then transplanted into mammary fat pads of WT mice.
Lung cells from old GFP MMT mice were used as a
positive control. Sixty days after cell inoculation, the
lungs harvested from WT recipient mice were processed
for colony-forming assay. As shown in Figure 5b (upper
panels), GFP expressing colonies were observed in the
lungs of GFP MMT mice as well as WT mice inoculated
with lung tissue cells. These colony cells also expressed
Sca1 (Figure 5b, lower panels). Interestingly, colonies
positive for GFP were observed in cultures of lung tissue
cells from mice as young as 20 days old, suggesting that
dissemination is an early event in this model of mam-
mary tumorigenesis. Furthermore, GFP expressing cells
without or with cell surface CD44 were found inside
blood vessels (Figure 5c). These results provide further
Figure 3 Tumorigenic potential of lung tissue cells from MMT mice.( a) Single-cell suspensions were isolated from lungs of mice double
transgenic for PyMT and MUC1 antigen (MMT) at the indicated ages, counted and then injected into the left and right mammary fat pads of
syngeneic wild-type (WT) mice at various doses. Eight weeks after inoculation, the recipient mice were sacrificed and the mammary glands were
harvested, processed for whole mount and photographed. WT mice injected with sorted CD44
+ mammary tumor cells or single-cell suspension
obtained from the lungs of MUC1.Tg mice were used as positive or negative controls, respectively. The solid masses indicated by circles are the
tumors. (b) Tumor incidence and tumor size in the whole mount were summarized and compared using one-way analysis of variance. (c and d)
The mammary glands as shown in (a) were processed for histology and (c) stained with H&E or anti-CD44 and Sca1 monoclonal antibodies by
(d)immunohistochemical (IHC) staining.
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Page 7 of 13Figure 4 Detection of disseminated and/or metastatic tumor cells in the new hosts. Single-cell suspensions from the lungs of mice double
transgenic for PyMT and MUC1 antigen (MMT) or MUC1 transgenic (MUC1.Tg) mice at indicated ages were injected into the fat pads of
mammary glands of wild type (WT) mice. Mice injected with sorted CD44
+ mammary tumor cells were used as controls. Eight weeks after the
inoculation, the lungs were harvested from the mice, perfused to remove the circulation cells, and then processed for clonogenic assay. (a)
Colonies from lung cell cultures of each mouse were counted and are presented in the bar graph. Statistical significance among groups was
compared using one-way analysis of variance. (b) Expression of estrogen receptor (ER) in some cells from colonies as shown in (a) using
immunocytochemical (ICC) staining. (c) Detection of MUC1/Sca1 positive tumor cells in lung tissue cells isolated from WT mice using ICC
staining. (d) Metastatic lesions in the lungs of WT mice injected with sorted CD44/Sca1
+ from mammary tumors (left two panels) or lungs of
MMT mice (right two panels). The lungs of recipient mice were processed for immunohistochemical (IHC) staining with anti-CD44 or anti-ER
monoclonal antibodies. The red square indicates the enlarged area.
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cells expressing CD44/Sca1 is endowed with disseminat-
ing and metastatic potential.
Differential tumorigenic and metastatic potential in the
subpopulations of lung and mammary epithelial/tumor
cells
We next determined differential tumorigenic and meta-
static potential in cell populations derived from lung or
mammary epithelial/tumor cells. CD44/Sca1
+ and
CD44/Sca1
- cell populations were sorted from the mam-
mary glands and lungs of GFP MMT mice at young (<
40 days) or old ages (> 120 days) and then injected into
the mammary fat pads of WT mice. Injection of CD44/
Sca1
+ cells from mammary tumors or lungs of MMT
mice resulted in the formation of tumors, regardless of
the donor age (Table 1). In contrast, none of the mice
inoculated with CD44/Sca1
- cells developed tumor. We
Figure 5 Detection of disseminated cells in WT recipient mice after inoculation with lung tissue cells from GFP MMT mice.( a)
Mammary glands harvested from mice transgenic for PyMT and MUC1 antigen (MMT) that also express green fluorescent protein (GFP MMT)
were processed for histological examination under light or fluorescence microscopy (60 x). (b) Colony-forming assay. WT mice were injected
with lung tissue cells isolated from GFP MMT mice at the indicated ages. Lungs were then collected and perfused to remove circulating cells.
Single-cell suspensions from the lungs were cultured in DMEM for two weeks. Colonies with GFP and Sca1 expression were observed under
fluorescence microscopy (lower panels). (c) Detection of GFP and CD44-positive cells in blood vessels of lung from a WT recipient mouse.
Samples from the recipient lungs were also processed for staining with H&E or anti-CD44 monoclonal antibodies.
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esis. Injection of as few as 2,000 CD44/Sca1
+ cells
resulted in the formation of tumors in the recipient
mice, while CD44/Sca1
- cells failed to form tumors (Fig-
ure 6a). Histological examination showed that these
tumors were positive for GFP and that some tumor cells
were also positive for CD44 (Figure 6b). These results
indicate the differential tumorigenic capacity between
CD44/Sca1
+ and CD44/Sca1
- cells.
We next compared the metastatic potential of CD44/
Sca1
+ and CD44/Sca1
- cells. Metastatic lesions were
found in the lungs of mice inoculated into the mam-
mary fat pad with CD44/Sca1
+ cells but not observed in
mice injected in a similar way with CD44/Sca1
- tumor
cells, regardless of donor age (Figure 6c). These meta-
static lesions expressed GFP and ESA or CD44 (Figure
6c). In addition, we quantified the levels of GFP-positive
cells in the blood, LN and lungs of recipient mice. As
shown in Figure 6d, injection of CD44/Sca1
+ tumor
cells resulted in the detection of 4.99 ± 0.5%, 1.77 ±
0.3%, and 3.56 ± 0.9% GFP and ESA double positive
(GFP/ESA
+) cells in the blood, LN and lungs, respec-
tively, of recipient mice. In contrast, only 0.04%, 0.03%,
and 0.03% GFP/ESA
+ cells were detected in the blood,
LN, and lungs of mice injected with CD44/Sca1
- cells.
Similar trends were observed in mice injected with
CD44/Sca1 positive or negative MECs from young GFP
MMT mice. GFP/ESA
+ cells were detected in the blood,
LN and lungs of recipient mice injected with CD44/Sca1
+ cells. In contrast, few GFP/ESA
+ cells were found in
these compartments of mice injected with CD44/Sca1
-
MECs (Figure 6d). Metastatic lesion positive for GFP
and ER was also found in the lungs of mice injected
with CD44/Sca1
+ cells from the lungs of GFP MMT
donor mice. In addition, GFP/ESA
+ cells were detected
in the blood, LN and lungs of recipient mice, regardless
of donor age (Figures 6e and 6f). These results further
confirm our findings that the CD44/Sca1
+ cell popula-
tion can play a major role in metastasis in MMT mice
and that tumorigenic and metastatic potential may exist
in cells early in mammary tumorigenesis.
Discussion
Breast cancer is initiated as a local disease but can also
seed metastases to distant organs; indeed the spread of
cancer cells from primary tumor sites to distant organs
accounts for the majority of deaths in breast cancer
patients [1]. Metastasis was thought to be a relatively
late event observed at tertiary stages of tumor progres-
sion and the result of sequential acquisition of genetic
variations in the cells that populate a neoplasm [3]. This
hypothesis is supported by the observation that metasta-
s i si sr a r e l yd i s c o v e r e di np a t i e n t sw i t hp r e m a l i g n a n t
lesions or non-invasive cancers. However, the absence of
metastasis at precancerous stages may not exclude the
possibility of dissemination of precancerous cells, which
may result in outgrowth and recurrence many years
later. Indeed, Engel and colleagues analyzed a total of
12,423 breast cancer patients with a median follow up
of 9.4 years. They estimated that the time from initia-
tion of metastases to its diagnosis was 5.8 years [29].
Based on subsequent analysis of 33,000 breast cancer
patients, the authors proposed that all metastases are
initiated before the removal of primary tumors and sug-
gested a model of parallel growth of primary and sec-
ondary tumors [30]. Animal studies by Husemann and
colleagues [16] showed disseminated tumor cells and
micrometastases in the bone marrows of mice trans-
planted with premalignant HER-2 transgenic glands. In
addition, the authors demonstrated the invasiveness of
cells with atypical ductal hyperplasia using electron
microscopy, suggesting migration potential for premalig-
nant cells. Using inducible oncogene activation, Posypa-
nina and colleagues [26] showed long-term survival of
normal MECs in the lungs. After the oncogenes myc
and ras or PyMT became activated by feeding with dox-
ycycline, mammary tumors developed in the lungs
within three to four weeks whereas transplantation of
retrieved MECs without oncogene activation into mam-
mary fat pad resulted in the formation of mammary
ductal trees. Although the MECs were directly injected
into the tail vein, thus bypassing the initial steps of
metastasis cascade, the authors provide unambiguous
evidence at least in their model that relatively normal
looking mammary cells can survive and undergo tumori-
genesis in ectopic site. These results support the model
of parallel development of primary and secondary
tumors at least in some malignancies. Consistent with
these findings, we have detected disseminated mammary
epithelial cells and metastasis in the lungs of MMT
mice as early as 26 and 60 days postnatal, respectively
(Figure 1). In 60-day-old MMT mice, mammary epithe-
lial cells appear to be at a premalignant stage of
Table 1 Tumorigenic potential of CD44/Sca1-positive cells
Sorted donor
cells
Donor age
(days)
Numbers of
recipient mice
Tumor
incidence
Tumor (+) cells > 120 4 4/4
Tumor (-) cells > 120 2 0/2
MECs (+) cells < 40 3 3/3
MECs (-) cells < 40 2 0/2
Lung (+) cells > 120 5 5/5
Lung (+) cells < 40 3 3/3
Lung (-) cells > 120 2 0/2
CD44/Sca1 positive (+) and CD44/Sca1 negative (-) cells were obtained by cell
sorting from tumor cells, mammary epithelial cells (MECs), or lungs of GFP
MMT mice at indicated ages and 8 × 10
4 cells were injected into the
mammary fat pads of wild type mice. Tumor incidence was determined 60
days after cell inoculation.
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Page 10 of 13progression. These experiments suggest that some
MECs from MMT mice are endowed early in tumori-
genesis with the capacity to complete the entire metas-
tasic cascade and that they migrate early in tumor
development [31]. When lung cells from these mice
were injected into the mammary fat pads of WT mice,
mammary tumors resembling the autochthonous tumor
developed (Figure 3). In addition, tumor cell colonies
were obtained from culture of lung tissue cells of recipi-
ent mice, suggesting that these cells maintain their
Figure 6 Tumorigenic and metastatic potential of CD44/Sca1
+ cells.C D 4 4 / S c a 1
+ and CD44/Sca1
- cells were obtained by cell sorting from
mammary epithelial cells (MECs), tumor cells or the lungs of mice transgenic for PyMT and MUC1 antigen (MMT) that also express green
fluorescent protein (GFP MMT) at different stages of tumor development and injected into the mammary fat pads of wild type (WT) mice at the
doses indicated (if not indicated in this way, 8 × 10
4 cells were injected). Tissue samples were obtained from WT mice injected with either
sorted CD44/Sca1
+ cells [(+)] or CD44/Sca1
- cells [(-)]. (a) Comparison of tumorigenic potential between CD44/Sca1
+ and CD44/Sca1
- tumor cells.
The tumor incidence and tumor size are presented for each group of mice inoculated with the indicated numbers of cells. (b) Mammary tumor
from a WT mouse inoculated with CD44/Sca1
+ tumor cells was viewed by H&E staining (left panel) and examined for GFP (middle panel) or
CD44 (right panel) expression using immunohistochemical (IHC) staining. (c) Sections of mammary glands from WT mice inoculated with CD44/
Sca1
+ tumor cells (> 120 days, upper panels) or MECs (< 40 days, lower panels) were stained with H&E and examined for expression of GFP and
ESA or CD44. (d) Quantification of disseminated cells. GFP-positive cells were gated from lung, lymph node cells (LNC) or blood cells of recipient
mice inoculated with CD44/Sca1
+ and CD44/Sca1
- cells from tumor cells or MECs of GFP MMT mice, and stained with anti-ESA monoclonal
antibodies and analyzed by FACS. (e) Tumors from the lungs of WT mice inoculated with CD44/Sca1
+ lung cells from GFP MMT mice at more
than 120 days were viewed by H&E staining and examined for GFP and estrogen receptor (ER) expression. (f) Quantification of disseminated
cells. GFP-positive cells were gated from lung, LNC or blood cells of recipient mice inoculated with CD44/Sca1
+ and CD44/Sca1
- cells from GFP
MMT mice at the indicated ages, stained with anti-ESA monoclonal antibodies and analyzed by FACS. (d and f) The average ± standard
deviation of ESA/GFP-positive cells in total blood, LN or lung cells were presented.
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mammary tumor to MMT lung metastasis, formation of
de novo tumors in WT hosts and in founding colonies
at distant sites in the recipient WT mouse (Figure 4).
The colony-forming assay is a very sensitive method to
detect disseminated tumor cells and micrometastasis
because only cells with extensive proliferative capacity
can form cell colonies [32]. However, normal stem cells
also possess unlimited proliferative ability and thus can
form cell colonies although we did not observe colony
f o r m a t i o ni nc u l t u r e so fl u n g tissue cells from control
MUC1.Tg mice (Figure 1c). To allay this concern, we
transplanted the lung tissue cells from MMT mice at
various stages of tumorigenesis into the mammary fat
pads of WT mice. The formation of mammary tumors
from these transplants indicates that the colony-forming
cells are tumor cells.
We performed three sets of experiments to identify
cells responsible for metastasis from primary tumors in
MMT mice. We first isolated the lung cells from MMT
mice at various stages of tumorigenesis and their tumor
initiation and metastasis were confirmed through trans-
plantation in WT mice (Figures 3 and 4). We next phe-
notyped the lung cells of MMT mice and found that
CD44/Sca1
+ cells were likely candidates for dissemi-
nated or metastatic cells (Figures 2 to 4). We finally
identified and sorted the CD44/Sca1
+ cells from mam-
mary epithelial/tumor cells of MMT mice at premalig-
nant and malignant stages of tumorigenesis. After
transplantation in WT mice, these cells developed pri-
mary and metastatic mammary tumors that resembled
the parent tumor and primary tumors derived from
transplantation with lung cells (Figures 4 and 6 and
Table 1), thus linking metastasis from PyMT-induced
primary breast carcinoma to a subset of cells with
tumor-initiation ability. It could be argued that tumor
formation by the lung cells in MMT mice is the result
of direct transformation by PyMT rather than dissemi-
nated mammary tumor cells. However, the expression of
PyMT is under the transcriptional control of the
MMTV promoter that is active specifically in mammary
epithelial cells. In MMTV-PyMT mice, high levels of
expression of the PyMT product were detected in
female mammary tumors, with lower levels detected in
the ovaries and salivary glands [24]. Although PyMT
w a sd e t e c t e di nt h el u n g so fo l d e rP y M Tm i c e ,l u n g -
specific expression was not observed in younger mice
and is correlated with the appearance of lung metastasis.
In addition, the lung tumors observed in our studies
resembled mammary tumors [23] (Figure 6). Thus it is
unlikely that lung tumors in MMT mice or tumors
derived from transplantation of lung cells resulted from
the lung epithelial cells induced by PyMT.
The GFP MMT mice may provide a useful model for
the study of metastasis of mammary carcinomas. For
example, disseminated and metastatic cells at various
stages of tumor development can be identified in the
various tissue compartments and characterized at the
cellular, molecular, and genetic levels. Moreover, the
model is particularly useful to evaluate early interven-
tion in the treatment of disseminated tumor cells or
micrometastasis. Such studies are currently underway.
Our results are also consistent with predictions under
the cancer stem cell hypothesis. We have demonstrated
that the MMTV-PyMT murine model of breast cancer
yields a consistent progression of spontaneous mammary
carcinomas with metastasis to the lung. We have shown
that tumorigenesis in the mammary glands of MMT
mice parallels the development of metastasis and that
cells which express putative stem cell markers may repre-
sent a population of cells important for the growth of
lung metastasis. We have also found that the subpopula-
tion of transformed mammary cells in the primary site or
in lungs to which metastasis has occurred can itself lead
to tumor growth in PyMT-negative hosts. These findings
suggest that cells with a stem cell phenotype play a causal
role in both tumorigenesis and metastasis.
Conclusions
The tumorigenic and metastatic potential of a subpopu-
lation of spontaneous tumors in MMT mice is endowed
relatively early in mammary tumorigenesis and suggests
a potential role for cancer stem/progenitor cell sub-
populations in metastasis.
Additional material
Additional file 1: Before and after lung perfusion. Lungs were
harvested prior to (upper panels) or after perfusion (lower panels). The
lung became pale after perfusion and histological examination shows
depletion of blood cells.
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